Noninvasive Monitoring of HPMA Copolymer–RGDfK Conjugates by Magnetic Resonance Imaging

PurposeTo evaluate the tumor targeting potential of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer–gadolinium(Gd)–RGDfK conjugates by magnetic resonance (MR) T1-mapping.MethodsHPMA copolymers with and without RGDfK were synthesized to incorporate side chains for Gd chelation. The conjugates were characterized by their side-chain contents and r1 relaxivity. In vitro integrin-binding affinities of polymeric conjugates were assessed via competitive cell binding assays on HUVEC endothelial cells and MDA-MB-231 breast cancer cells. In vivo MR imaging was performed on MDA-MB-231 tumor-bearing SCID mice at different time points using non-targetable and targetable polymers. The specificity of αvβ3 targeting was assessed by using non-paramagnetic targetable polymer to block αvβ3 integrins followed by injection of paramagnetic targetable polymers after 2 h.ResultsThe polymer conjugates showed relaxivities higher than Gd-DOTA. Endothelial cell binding studies showed that IC50 values for the copolymer with RGDfK binding to αvβ3 integrin-positive HUVEC and MDA-MB-231 cells were similar to that of free peptide. Significantly lower T1 values were observed at the tumor site after 2 h using targetable conjugate (p < 0.012). In vivo blocking study showed significantly higher T1 values (p < 0.045) compared to targetable conjugate.ConclusionThese results demonstrate the potential of this conjugate as an effective targetable MR contrast agent for tumor imaging and therapy monitoring.

[1]  M Schwaiger,et al.  Tumor angiogenesis targeting using imaging agents. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[2]  A. Rademaker,et al.  Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Z. Lu,et al.  HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  H. Ghandehari,et al.  Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[6]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[7]  D. Parker,et al.  RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. , 2007 .

[8]  David M Higgins,et al.  Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution--reproducibility study. , 2006, Radiology.

[9]  K. Craig Goodrich,et al.  The Arthrotropism of Macromolecules in Adjuvant-Induced Arthritis Rat Model: A Preliminary Study , 2004, Pharmaceutical Research.

[10]  J. Kopeček,et al.  Poly[N-(2-hydroxypropyl)methacrylamide]-iii. Crosslinking copolymerization , 1974 .

[11]  J. Papadimitriou,et al.  Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. , 2006, Nuclear medicine and biology.

[12]  X. Li,et al.  The Gd(3+) complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. , 2001, Inorganic chemistry.

[13]  J. Kopeček,et al.  Poly[N‐(2‐hydroxypropyl)methacrylamide]. IV. Heterogeneous polymerization , 1978 .

[14]  D. Parker,et al.  Noninvasive Visualization of Pharmacokinetics, Biodistribution and Tumor Targeting of Poly[N-(2-hydroxypropyl)methacrylamide] in Mice Using Contrast Enhanced MRI , 2007, Pharmaceutical Research.

[15]  S. Gambhir,et al.  microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .

[16]  David W Townsend,et al.  Image‐Guided Cancer Therapy Using PET/CT , 2004, Cancer journal.

[17]  S. Gambhir,et al.  microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  H. Ghandehari,et al.  Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  D. Parker,et al.  PEG-g-poly(GdDTPA-co-L-cystine): effect of PEG chain length on in vivo contrast enhancement in MRI. , 2005, Biomacromolecules.

[20]  H. Ghandehari,et al.  Polymeric conjugates of mono- and bi-cyclic αvβ3 binding peptides for tumor targeting , 2006 .

[21]  E Biganzoli,et al.  Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  V. Torchilin,et al.  Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. , 2006, Molecular pharmaceutics.

[23]  E. Maxwell,et al.  Biochemical Characterization of the Binding of Echistatin to Integrin αvβ3 Receptor , 1997 .

[24]  M. Bock,et al.  Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. , 2006, Bioconjugate chemistry.

[25]  Sandra Geyser-Stoops,et al.  Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[26]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[27]  P. Kam,et al.  : 4 , 1898, You Can Cross the Massacre on Foot.

[28]  William E Grizzle,et al.  Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. , 2008, Radiology.

[29]  W. Cai,et al.  Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression. , 2008, Frontiers in bioscience : a journal and virtual library.

[30]  J. Labský,et al.  Aminolyses of monomeric and polymeric 4‐nitrophenyl esters of N‐methacryloylamino acids , 1977 .

[31]  P. Black,et al.  Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. , 2001, Neurosurgery.

[32]  H. Ghandehari,et al.  Targeting tumor angiogenic vasculature using polymer-RGD conjugates. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[33]  S. Ray,et al.  Role of alphavbeta3 integrin receptors in breast tumor. , 2001, Journal of experimental & clinical cancer research : CR.

[34]  R. Gullapalli,et al.  HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation. , 2008, Macromolecular bioscience.

[35]  E. Maxwell,et al.  Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. , 1997, The Journal of pharmacology and experimental therapeutics.

[36]  Stefan Neubauer,et al.  Ultra‐fast and accurate assessment of cardiac function in rats using accelerated MRI at 9.4 Tesla , 2008, Magnetic resonance in medicine.

[37]  J. Wittenberg,et al.  Gd-DOTA: characterization of a new paramagnetic complex. , 1988, Radiology.

[38]  Ji-Kyung Choi,et al.  Exogenous contrast agent improves sensitivity of gradient‐echo functional magnetic resonance imaging at 9.4 T , 2004, Magnetic resonance in medicine.

[39]  P. Joseph,et al.  Nuclear magnetic resonance and gamma camera tumor imaging using gadolinium-labeled monoclonal antibodies. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  R. Gullapalli,et al.  Macrophage targeted N-(2-hydroxypropyl)methacrylamide conjugates for magnetic resonance imaging. , 2006, Molecular pharmaceutics.

[41]  J. Kopeček,et al.  Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. , 1987, Journal of biomedical materials research.